retatrutide approved where Retatrutide, an experimental weight-loss drug, has not been by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation New Weight Loss Drug Retatrutide:

This is the strongest peer-reviewed human evidence in the T4 family, although the formulation tested was full-length T4, not the TB-500 fragment used in commercial peptide products

What are the safety concerns

Glutathione defense mechanism in liver injury: insights from animal models

Retatrutide (LY3437943) is a peptide developed by Eli Lilly that acts on three different metabolic receptors simultaneously: GLP-1 receptor GIP receptor Glucagon receptor This makes Retatrutide the first triple-agonist peptide to reach advanced Phase 3 clinical development

It is most often chosen for overall skin radiance, an uneven complexion, and tan or melasma-related dullness